AstraZeneca bets on Kendall Square R&D hub to power next phase of growth
AstraZeneca has opened a major research and development center in Cambridgeโs Kendall Square, a move that underscores the drugmakerโs determination to deepen its U.S. innovation footprint and sustain growth well beyond the current decade. The company says the site, backed by more than $1 billion in investment in Massachusetts, is designed to accelerate discovery with advanced automation, robotics and a denser concentration of scientific talent.
